Core Viewpoint - Junshi Biosciences-U's stock price has shown a positive trend, reflecting investor confidence in the company's ongoing drug development and recent regulatory progress [1] Company Overview - Junshi Biosciences-U is a biopharmaceutical company focused on the research, development, production, and commercialization of innovative drugs [1] - The company's main products include Toripalimab and other biological drugs, targeting areas such as tumor immunotherapy, metabolic diseases, and autoimmune diseases [1] Recent Developments - The National Medical Products Administration has accepted the new indication application for Toripalimab in combination with Vedolizumab for patients with locally advanced or metastatic urothelial carcinoma expressing HER2 [1] - This marks the 13th indication application for Toripalimab submitted in China [1] Market Performance - As of August 11, 2025, Junshi Biosciences-U's stock price was 42.54 yuan, up by 1.03 yuan or 2.48% from the previous trading day [1] - The stock opened at 41.60 yuan, reached a high of 43.50 yuan, and a low of 40.81 yuan, with a trading volume of 230,900 hands and a transaction amount of 966.7 million yuan [1] - The net outflow of main funds on August 11, 2025, was 15.63 million yuan, accounting for 0.05% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds was 40.99 million yuan, representing 0.13% of the circulating market value [1]
君实生物-U股价上涨2.48% 特瑞普利单抗第13项适应症申请获受理